



# Biotech Daily

Wednesday July 27, 2022

*Daily news on ASX-listed biotechnology companies*

- \* **ASX UP, BIOTECH EVEN: ALCIDION UP 15%; ANTISENSE DOWN 7%**
- \* **MEDADVISOR RIGHTS RAISE \$14.6m**
- \* **ALCIDION RECEIPTS UP 29% TO \$41m**
- \* **GENETIC SIGNATURES RECEIPTS UP 31% TO \$39m**
- \* **RESAPP \$4.5m RECEIPTS, \$4.2m FROM PFIZER LICENCE**
- \* **NUHEARA RECEIPTS DOWN 53% TO \$4.1m**
- \* **4D WELCOMES US BILLS BACKING VETERANS' 4-DIMENSIONAL X-RAYS**
- \* **CORRECTION: IMMURON**
- \* **MTP CONNECT: 2<sup>nd</sup> ROUND CLINICAL TRANSLATION PROGRAM**
- \* **CRESO REQUESTS CAPITAL RAISING TRADING HALT**
- \* **DORSAVI REQUESTS CAPITAL RAISING TRADING HALT**
- \* **MEMPHASYS REQUESTS CAPITAL RAISING TRADING HALT**
- \* **DIRECTOR PETER FORD TAKES 27% OF CONTROL BIONICS**
- \* **MASON STEVENS REDUCES TO 7.7% OF PATRYS**

## MARKET REPORT

The Australian stock market was up 0.23 percent on Wednesday July 27, 2022, with the ASX200 up 15.9 points to 6,823.2 points. Fifteen of the Biotech Daily Top 40 stocks were up, 15 fell, seven traded unchanged and three were untraded. All three Big Caps were up.

Alcidion was the best, up two cents or 14.8 percent to 15.5 cents, with 16.2 million shares traded. Atomo was up 10.8 percent; both Clinuvel and Impedimed improved eight percent; Compumedics and Volpara climbed more than five percent; Kazia and Micro-X were up more than three percent; Amplia, Nova Eye and Pro Medicus rose more than two percent; CSL, Immutep, Neuren and Oncosil were up one percent or more; with Cochlear, Resmed and Starpharma up by less than one percent.

Antisense led the falls, down 0.6 cents or 7.1 percent to 7.8 cents, with 484,553 shares traded. Paradigm lost 5.1 percent; Genetic Signatures, Next Science, Patrys and Pharmaxis fell more than four percent; Emvision and Universal Biosensors were down more than three percent; Imugene, Polynovo and Telix shed more than two percent; Nanosonics was down 1.4 percent; with Avita, Mesoblast and Opthea down by less than one percent.

## MEDADVISOR

Medadvisor says it has raised \$10 million in its institutional rights offer at 14 cents a share and will raise a further \$4.6 million in a fully underwritten retail rights offer.

On Monday, Medadvisor said it would acquire Sydney's Guildlink for \$9.14 million and hoped to raise \$14.6 million in a one-for-4.2 entitlement offer (BD: Jul 25, 2022).

Medadvisor was up half a cent or 3.6 percent to 14.5 cents.

## ALCIDION

Alcidion says that receipts from customers for the year to June 30, 2022 was up 29.3 percent to \$41,449,000 compared to previous corresponding period.

Alcidion said receipts from sales and use of its hospital management systems for the three months to June 30 improved 43.9 percent to \$13,960,000, it was \$3,310,000 cashflow positive for the three months to June 30, with cash and cash equivalents of \$17,339,000.

Alcidion was up two cents or 14.8 percent to 15.5 cents with 16.2 million shares traded.

## GENETIC SIGNATURES

Genetic Signatures says receipts from customers for the year to June 30, 2022 was up 31.2 percent to \$39,405,000 compared to the previous corresponding period.

Genetic Signatures said customer receipts for the three months to June 30, for its enteric protozoan, respiratory and severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) detection test kits, were up 0.6 percent to \$5,148,000, it had a cash burn of \$169,000 at June 30, with cash and equivalents of \$36,897,000.

Genetic Signatures fell five cents or 4.55 percent to \$1.05.

## RESAPP HEALTH

Resapp says receipts from customers for the year to June 30, 2022 was \$4,516,000 of which \$4,056,000 received under its licence deal with Pfizer.

In June, Resapp said Pfizer Australia would offer 14.6 cents a share to buy the company, valuing it at \$125 million (BD: Jun 21, 2022).

Today, Resapp said other revenue came from Sleepcheck downloads and Resappdx use, as well as additional advanced payments from Janssen (BD: Nov 18, 2021)

The company said it was \$636,000 cashflow positive at June 30 and had \$2,290,000 in cash and cash equivalents.

Resapp was up half a cent or 4.35 percent to 12 cents with 4.45 million shares traded.

## NUHEARA

Nuheara says receipts from customers for the year to June 30, 2022 were down 53.4 percent to \$4,122,000 compared to the previous corresponding period.

Nuheara said that customer receipts for its Elite Wireless Earbuds for Hewlett Packard and Iqbuds2 Max for the three months to June 30 were down 68.3 percent to \$600,000.

The company said it had a cash burn of \$1,971,000 for the three months to June 30, with \$412,000 in cash and equivalents and 0.2 quarters of funding available.

Nuheara said that on July 1 it announced a \$2.05 million placement with partner Realtek subscribing for \$1.7 million, along with a loan of \$1,118,052 against its expected Federal Research and Development Tax Incentive (BD: Jul 1, 2022).

Nuheara fell two cents or 7.7 percent to 24 cents.

## 4D MEDICAL

4D Medical says two Bills before the US Congress call for the evaluation of four-dimensional lung function x-ray and it is the only known company to provide that service. 4D Medical said that passage of both the 'Sergeant First Class Heath Robinson Honoring Our Promise to Address Comprehensive Toxics (PACT) Act' and HR 8294 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023' would fund a program to evaluate "emerging technology using existing x-ray imaging equipment to derive four-dimensional models of lung function".

The company said that the Appropriates Act states that "the Committee urges the Department [of Veterans Affairs] to evaluate this technology for the purposes of conducting population-wide surveillance of veterans who have likely been exposed to airborne hazards, in order to conduct a full accounting of the health impacts suffered by veterans and to provide full and effective medical care to this population".

4D said that "burn pit population surveillance" was important because the use of burn pits to destroy material might be the cause of hard to diagnose respiratory illnesses.

4D chief executive officer Prof Andreas Fouras said the "four-dimensional scanning is one of those 'emerging technologies' available right now to help veterans suffering from respiratory illness".

"We are starting to grasp the true health impacts for many of the 3.5 million veterans who served overseas since September 11, 2001 and now suffer from incurable respiratory diseases which existing technologies fail to detect," Prof Fouras said.

"That process starts with an advanced, yet convenient, screen," Prof Fouras said.

4D said the US House of Representatives had passed the PACT Act which was expected to pass the Senate next week and be signed subsequently by US President Joe Biden.

The company said the Bill established "a presumption of service connection for 23 respiratory illnesses and cancers related to the smoke from military burn pits and other toxic exposures ... [and] streamlines the process by which veterans apply for disability benefits to cover the cost of their treatment".

4D said the use of effective screening technologies addressed in the Appropriations Bill would "help serve the veterans population covered under the PACT Act".

The Bills are before the US Congress and require both chambers to pass them, to be followed by signing into law by the President.

4D Medical was unchanged at 61 cents.

## CORRECTION: IMMURON

Last night's edition incorrectly said the US Food and Drug Administration wanted more information for a drug application for two trials of Travelan.

In fact, the trial is not of the company's registered over-the-counter Travelan for travellers diarrhoea but the separate cow colostrum-based Campetec which the US Naval Medical Research Centre hopes to trial for campylobacteriosis and enterotoxigenic Escherichia coli-induced diarrhoea (BD: May 11, 2022).

Immuron chief executive officer Steve Lydeamor told Biotech Daily the company had three compounds under investigation: IMM-124E, the ingredient in Travelan, for enterotoxigenic Escherichia coli-induced diarrhoea; IMM-529 for Clostridioides difficile; and Campetec for campylobacteriosis and enterotoxigenic Escherichia coli-induced diarrhoea.

The mistake was made by the Tuesday sub-editor who complained of stomach cramps during the day and has been given a week's unpaid sick leave and told to take more Travelan ... and chicken soup.

Immuron fell 0.2 cents or 2.3 percent to 8.6 cents.

### MTP CONNECT

MTP Connect says a second and final round of its Clinical Translation and Commercialisation Medtech Program will open in September 2022.

MTP Connect said the program, funded by the Medical Research Future Fund, would provide grants between \$250,000 to \$1.5 million to accelerate the development of medical devices for human use, delivered over a maximum 24-month period.

The organization said the program was targeting any Australian “medical device for human use, the purpose of which is to diagnose, prevent, monitor, treat or alleviate a disease or injury, or modify or monitor anatomy or physiological functions of the body”.

MTP Connect said the program would fund prototype development, product testing, clinical trial activity, regulatory support, and it would consider other stages of development.

MTP Connect chief executive officer Stuart Dignam said the program was aimed at devices whose capability had been validated with research and/or preclinical studies.

“Applicants will also be required to provide a cash co-contribution dependent on the total ... program funding request, with additional in-kind or cash contributions above this threshold viewed favorably,” Mr Dignam said.

“Applicants will be supported throughout the 24-month period with valuable educational support, consultation and access to critical engineering, fabrication and prototyping facilities to help accelerate translation of their medical device,” Mr Dignam said.

MTP Connect said an information session would be held in Brisbane and virtually on August 23, 2022 at 1pm (AEST). To register, go to: <https://bit.ly/3oEluEd>.

### CRESO PHARMA

Creso has requested a trading halt “pending an announcement regarding a capital raising”.

Trading will resume on July 29, 2022 or on an earlier announcement.

Creso last traded at 4.9 cents.

### DORSAVI

Dorsavi has requested a trading halt “pending an announcement ... in relation to a proposed capital raising”.

Trading will resume on July 29, 2022 or on an earlier announcement.

Dorsavi last traded at 1.4 cents.

### MEMPHASYS

Memphasys has requested a trading halt pending an announcement “regarding a capital raising”.

Trading will resume on July 29, 2022 or on an earlier announcement.

Memphasys last traded at 4.5 cents.

### CONTROL BIONICS

Control Bionics executive director Peter Ford says he has increased his substantial holding in the company from 21,258,313 shares (25.51%) to 24,826,173 shares (27.43%).

The Sydney-based Mr Ford said that on July 25, 2022, he acquired 3,567,860 shares through the exercise of options for \$749,250, or 21.0 cents a share.

Control Bionics fell 2.5 cents or 10.9 percent to 20.5 cents.

## PATRY5

Mason Stevens says that between July 23, 2021 and April 13, 2022, it increased then reduced its Patrys holding from 113,818,783 shares (6.26%) to 158,735,837 shares. In three separate substantial filings, the Sydney-based Mason Stevens said that it bought and sold shares in Patrys in a large number of small transactions, with the largest single sale 1,259,915 shares for \$46,463, or 3.7 cents a share.

The company said it held 188,815,565 shares (9.92%) at November 8, 2021 and 180,255,348 shares (8.76%) at January 7, 2022

Patrys fell 0.1 cents or 4.35 percent to 2.2 cents.